In October 2005, clobetasol, 0.05%, spray (Clobex spray; Galderma Laboratories LP, Fort Worth, Texas), received US Food and Drug Administration (FDA) approval for treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in patients 18 years or older.1 A few months thereafter, I received a brochure inviting me to be an investigator in a study of Clobex spray that was called “CoBRA,” an acronym for Community-Based Research Assessment.2 “Join Us as an Investigator,” the brochure read.2(p1) It continued2(p2):
Katz KA. Time to Nip “Seeding Trials” in the Bud. Arch Dermatol. 2008;144(3):403–404. doi:10.1001/archderm.144.3.403
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: